STELLA PHARMA CORPORATION [4888.T]
TOKYO, Apr 28 (Pulse News Wire) – Stella Pharma Corporation (4888.T) reported progress in transferring production of its product Stebolonin® to a new manufacturing partner. As previously disclosed on January 22, 2026, the company completed pilot plant trials by December 31, 2025, followed by commercial plant testing in April 2026, confirming quality suitability.
Currently, preparations for process validation are underway, with plans to apply for partial approval changes due to manufacturing site alterations in August 2026. Approval is anticipated around January 2027. Post-acquisition, the company aims to commence full-scale production.
All costs associated with this transition have been incorporated into the revised fiscal year 2026 performance forecast and the medium-term management plan for fiscal year 2027. In addition, discussions with PMDA (Pharmaceuticals and Medical Devices Agency) ensure stable supply without disrupting product availability. The company prioritizes rebuilding a robust supply system and will continue efforts to maintain market product delivery.
Any further developments related to this matter will be promptly communicated.
🟢 Confidence: High AI-translated content.